Editorial: Engineered immune cells in cancer immunotherapy (EICCI)
Francisco Martin,
Axel Schambach,
Axel Schambach,
Cristina Maccalli,
Cristina Maccalli
Affiliations
Francisco Martin
Gene and Cell Therapy group, Departamento de Bioquimica y Biología molecular 3 e inmunología, Universidad de Granada, Center Pfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research, Granada-Junta de Andalucía Centre for Genomics and Oncological Research (GENYO), Granada, Spain
Axel Schambach
Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany
Axel Schambach
Division of Hematology/Oncology, Boston Children’s Hospital, Harvard Medical School, Boston, MA, United States
Cristina Maccalli
Research Department, Sidra Medicine, Doha, Qatar
Cristina Maccalli
College of Health and Life Science, Hamad bin Khalifa University, Doha, Qatar
